These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 12773040)

  • 1. Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.
    Tarzia G; Duranti A; Tontini A; Piersanti G; Mor M; Rivara S; Plazzi PV; Park C; Kathuria S; Piomelli D
    J Med Chem; 2003 Jun; 46(12):2352-60. PubMed ID: 12773040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.
    Mor M; Rivara S; Lodola A; Plazzi PV; Tarzia G; Duranti A; Tontini A; Piersanti G; Kathuria S; Piomelli D
    J Med Chem; 2004 Oct; 47(21):4998-5008. PubMed ID: 15456244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and quantitative structure-activity relationship of fatty acid amide hydrolase inhibitors: modulation at the N-portion of biphenyl-3-yl alkylcarbamates.
    Mor M; Lodola A; Rivara S; Vacondio F; Duranti A; Tontini A; Sanchini S; Piersanti G; Clapper JR; King AR; Tarzia G; Piomelli D
    J Med Chem; 2008 Jun; 51(12):3487-98. PubMed ID: 18507372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of FAAH inhibitors: cyclohexylcarbamic acid biphenyl esters with chemical modulation at the proximal phenyl ring.
    Tarzia G; Duranti A; Gatti G; Piersanti G; Tontini A; Rivara S; Lodola A; Plazzi PV; Mor M; Kathuria S; Piomelli D
    ChemMedChem; 2006 Jan; 1(1):130-9. PubMed ID: 16892344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation.
    Fegley D; Gaetani S; Duranti A; Tontini A; Mor M; Tarzia G; Piomelli D
    J Pharmacol Exp Ther; 2005 Apr; 313(1):352-8. PubMed ID: 15579492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-Heterocycle-phenyl N-alkylcarbamates as FAAH inhibitors: design, synthesis and 3D-QSAR studies.
    Käsnänen H; Myllymäki MJ; Minkkilä A; Kataja AO; Saario SM; Nevalainen T; Koskinen AM; Poso A
    ChemMedChem; 2010 Feb; 5(2):213-31. PubMed ID: 20024981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters.
    Basso E; Duranti A; Mor M; Piomelli D; Tontini A; Tarzia G; Traldi P
    J Mass Spectrom; 2004 Dec; 39(12):1450-5. PubMed ID: 15578755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and evaluation of paracetamol esters as novel fatty acid amide hydrolase inhibitors.
    Onnis V; Congiu C; Björklund E; Hempel F; Söderström E; Fowler CJ
    J Med Chem; 2010 Mar; 53(5):2286-98. PubMed ID: 20143779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of computational methods to the design of fatty acid amide hydrolase (FAAH) inhibitors based on a carbamic template structure.
    Lodola A; Rivara S; Mor M
    Adv Protein Chem Struct Biol; 2011; 85():1-26. PubMed ID: 21920320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase.
    De Simone A; Russo D; Ruda GF; Micoli A; Ferraro M; Di Martino RM; Ottonello G; Summa M; Armirotti A; Bandiera T; Cavalli A; Bottegoni G
    J Med Chem; 2017 Mar; 60(6):2287-2304. PubMed ID: 28182408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.
    Solinas M; Tanda G; Justinova Z; Wertheim CE; Yasar S; Piomelli D; Vadivel SK; Makriyannis A; Goldberg SR
    J Pharmacol Exp Ther; 2007 Apr; 321(1):370-80. PubMed ID: 17210800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.
    Ortar G; Cascio MG; De Petrocellis L; Morera E; Rossi F; Schiano-Moriello A; Nalli M; de Novellis V; Woodward DF; Maione S; Di Marzo V
    J Med Chem; 2007 Dec; 50(26):6554-69. PubMed ID: 18027904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structure-activity relationship studies of O-biphenyl-3-yl carbamates as peripherally restricted fatty acid amide hydrolase inhibitors.
    Moreno-Sanz G; Duranti A; Melzig L; Fiorelli C; Ruda GF; Colombano G; Mestichelli P; Sanchini S; Tontini A; Mor M; Bandiera T; Scarpelli R; Tarzia G; Piomelli D
    J Med Chem; 2013 Jul; 56(14):5917-30. PubMed ID: 23822179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase.
    Bisogno T; Melck D; De Petrocellis L; Bobrov MYu ; Gretskaya NM; Bezuglov VV; Sitachitta N; Gerwick WH; Di Marzo V
    Biochem Biophys Res Commun; 1998 Jul; 248(3):515-22. PubMed ID: 9703957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthesis and biological evaluation of para-substituted phenolic N-alkyl carbamates as endocannabinoid hydrolyzing enzyme inhibitors.
    Minkkilä A; Myllymäki MJ; Saario SM; Castillo-Melendez JA; Koskinen AM; Fowler CJ; Leppänen J; Nevalainen T
    Eur J Med Chem; 2009 Jul; 44(7):2994-3008. PubMed ID: 19232787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ω-Imidazolyl- and ω-Tetrazolylalkylcarbamates as Inhibitors of Fatty Acid Amide Hydrolase: Biological Activity and in vitro Metabolic Stability.
    Terwege T; Hanekamp W; Garzinsky D; König S; Koch O; Lehr M
    ChemMedChem; 2016 Feb; 11(4):429-43. PubMed ID: 26732805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors.
    Dickason-Chesterfield AK; Kidd SR; Moore SA; Schaus JM; Liu B; Nomikos GG; Felder CC
    Cell Mol Neurobiol; 2006; 26(4-6):407-23. PubMed ID: 16736384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
    Vincent F; Nguyen MT; Emerling DE; Kelly MG; Duncton MA
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6793-6. PubMed ID: 19850474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate.
    Vandevoorde S; Fowler CJ
    Br J Pharmacol; 2005 Aug; 145(7):885-93. PubMed ID: 15895107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent α-amino-β-lactam carbamic acid ester as NAAA inhibitors. Synthesis and structure-activity relationship (SAR) studies.
    Nuzzi A; Fiasella A; Ortega JA; Pagliuca C; Ponzano S; Pizzirani D; Bertozzi SM; Ottonello G; Tarozzo G; Reggiani A; Bandiera T; Bertozzi F; Piomelli D
    Eur J Med Chem; 2016 Mar; 111():138-59. PubMed ID: 26866968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.